•
•
~~
fi~
I:i!le
~.
~11
-~~
.&.I.&.. ~.ti
-•
Ifi
':::'itt
~
~ ...co
fa€~.
~v
P<1t~
rn
rn
~
~~"
"
.
v
or-m!9I!.
-~~~~
:ltttii
~
P-:I~~
~
~.
gJK
IB[~~
II
lMD
~
~
~, 'T ~*: ~I
liF.l:
lj ~~j ~tH :z ~t 1 ~~ tpL..1I ~q:s. ITt:u
"'-' Il a;;1:t jf[/J fP ~jj\ lit 'l~ ~jJlj ~~i r... rc·§ ~~ rpt=.lt< ~fT. C, ~J!;:,: ix f.~ ~8- 2 1-1 .',,,,. o/lij 1-2li
~x.~ 1~~~* ~JlJJJlHilfi.Jt
27 ( #JE~B ' 5~f,Bffx ) 2-1-{jHiW
( General Characteristics ) 322-2 ~~ ~:t ~ ( Clinical Significance) 33
2-3
±g
*"~.;f,ti.&Jt1i.7i
~ ( Cultural Characteristics & ldentification ) 44r_...
(!}B~It)3-1 - ~
H
.
W
(General Characteristics) 52 3-2 ~iJt.:t,n ( Clinical Significance) 543-3
:Ig-'l!t+'ti.&.$tR7JA:
( Cultural Characteristics & Identification ) 543-4 ~
W
f,iJ
~'ti
tt~ ( Antimicrobial Susceptibility Testing) 563-5 ~
Wi
/
5tt
IT.:iN ~
( Prevention / Epidemiology ) 583-6 ~ fVlJ
li1f'1..
( Case Study) 59(~B~It)
4-1 -
A9:
,tt
~ ( General Characteristics ) 624-2 ~.Th
'*
~i ( Clinical Significance ) 624-3 ±15
*"
#-
,tt
Jjz ~;t1i
A;; ( Cultural Characteristics & Identification) 644-4 ~~m ~~,titt~t (Antimicrobial Susceptibility Testing) 66 4-5 "ffl
!lfl
/
5*
rr
~*
( Prevention / Epidemiology ) 674-6
m
i7~ffl
~ (Case Study ) 67(~~m)
5-1 -
hHi
J
(General Characteristics ) 72 5-2 ~ t*.~~ ( Clinical Significance ) 735-3
±g.:i-4f'tilHIJt7i:7i
( Cultural Characteristics & Identification ) 745-4 ~#J~~'li~~ ( Antimicrobial Susceptibility Testing ) 78
x xi " ~ 5-6 ~ i9~
Wf
~ ( Case Study ) 81(
~~tf )6-1
-A9:,ti}t
( General Characteristics ) 86 6-21m *;t,
i; (Clinical Significance ) 876-3
±-g:,*#
·ti:&.~;z:t-)! (Cultural Characteristics & Identification) 886-4 ~4fJJ ~~
U
.
~~~ (Antimicrobial Susceptibility Testing ) 89~*
6-5 ffJ pjj/ if[iT
~ ~ ( Prevention / Epidemiology ) 90~
t+JU
"'if! 6-6
ffl
i9'J ~11:. ( Case Study ) 91~ L
,
(~tLiE
)
~~: 7-1 -
M
.
't!
';! ( General Characteristics ) 967-2 liJ;lildi~ ( Clinical Significance) 97
~ (~J..1iE )
10-1
-
~9:·tt1t
(General Characteristics ) 12210-2 ~£
*;t,
i
( Clinical Significance) 12310-3
±g
'~!f+·ti.&.
~;tff)! (Cultural Characteristics & 1dentification) 12710-4
-
#J M
~·tt~,~ ( Antimicrobial Susceptibility Testing) 138 10-5fflilt
/
1if.1i
#ii
~ ( Prevention / Epidemiology ) 14410-6 ~
19
IJ ~ ~ ( Case Study ) 146( ;'i /J\5$ )
11-1
-
~~·tiJ
( General Characteristics ) 15011-2 ~~
*
~it
(Clinical Significance) 15111-3
tg*"ij;f
·
ti.&Jttt7J
5l-
(Cultural Characteristics & fdentification ) 16211 -4 ~
#J
~'Jt
'ti
tt.lYk
( Antimicrobial Susceptibility Testing ) 17111-5
ffi
~jj /.;tt
IT
~ ~ ( Prevention / Epidemiology ) 171~~l 98
7-3
±
g
*-
4~'tibHfi ~j]
Ai:
( Cultural Characteristics & Identification)f
l
,
!
'-'- 11 -6 mi9~
¥f
~ ( Case Study) 1717-4 ~ ~m ~~
·ti
~~ ( Antirillcrobial Susceptibility Testing ) 102~1
n 7-5
ffi
WI
/
$trr
~ ~ ( Prevention / Epidemiology ) 102.
-'.~~~ 7-6 ~i9IJtiJ!-JL ( Case Study ) 102
12-1 -
A9:
·
ti
jt ( General Characteristics) 176~q:E
(
~l-:LlE)
12-21m
*;t:lt
(Clinical Significance) 17812-3 :l-tH~*f'ti.&.~;t7f)i (Cultural Characteristics & Identification) 179
...., 8-1 -
h9:
·ti
jf[ (General Characteristics ) 10612-4 ~w~~·ti~~ (Antimicrobial Susceptibility Testing) 187
5::::1i 8-2 ~~*jt;ft (Clinical Significance) 106
"'/ ) 12-5
ffi
P.t
/
5JiE fT~ ~ ( Prevention / Epidemiology ) 1888-3 :l:fH~·tHi:&' ~Jt
7J
*
(Cultural Characteristics & Identification ) 10712-6 ~i9n~D'E (Case Study ) 189
8-4 ~
#J ~
1t'riv\'~ ( Antimicrobial Susceptibility Testing ) 109~
/-8-5
ffl
~n/
5)itif
~!f. ( Prevention / Epidemiology ) 110~;~ 8-6
ffJ
i91
~~ (Case Study ) 111n ( ~~t~ )
J i t
13-1
- AlHi 91
( General Characteristics ) 194mifr
9-1 -
AHi
it
(General Characteristics ) 114 13-2 ~.lj;'*
:t,n
( Clinical Significance ) 197B~i 13-3
±g
*~·tilH.l~:ffAi:
(Cultural Characteristics & ldenl'ification ) 199( ~l-ilE
)
9-2 ~~ ~
i:.i
(Clinical Significance) 115... ~ 116 13-4 ~~
(TI-ealment ) 202
r:p'-f 9-3
±
g
*4~,tilkit
J:t7J
*
(Cultural Characteristics & Identification)I
I
.
9-4 •
#J
M-
~.t!$\~ ( Antimicrobial Susceptibi lity Testing ) 118 13-5 tri P1i / 5fif,i
T
~:$ ( Prevention / Epidemiology ) 203~~
~f~ 9-5 fff!I;Q / S:nf.
rr
1rtJ!:Q:. ( Prevention / Epidemiology ) 11 8 13-6WJ
ifl] \i}f ~ ( Case Study ) 204ff!~f1 9-6 ~-WI] :{iJD'E ( Case Study ) 120
't:;t
~ ~~ U :J CiJ3
5
R
5N
5
N
:
5N
l
t+l1J.. ~~H Ii 7 ± / J f1~ 1: ~/. ~j~ nmj
fl
I B~~ I Inl :P::-I ~~""
~¥. I xii (f1iJii~)
14-1 - ~,tt
~ ( General Characteristics) 210 14-2 ~~.DR!: ~ (Clinical Significance ) 21614-3
115
fi
¥t ,tt&
~.it jj)!: ( Cultural Characteristics & Identification ) 22 1L4-4 ~#J ~ j:,ti~. $ ( Antimicrobial Susceptibility Testing ) 23 3
14-5
ffi
1l1J
/
)tEiT
~ ~ ( Prevention I Epidemiology ) 235 14-6 ~ ~IJiiJf
Jt
(Case Study ) 236(OO,filt
)
15] -
A(( '
r!
J
(General Characteristics ) 24215-2 ~~~
'*
jt~ ( Clinical Significance ) 24215-3 ±~~4-Hi'& ~.it7f
A:
( Cultural Characteristics & Identification ) 24415-4 ~~m ~ ~·Iit~. ~ ( Antimicrobial Susceptibility Testing) 247
15-5
ffI
flfr
/
5JiEh
m
~ ( Prevention / Epidemiology ) 24815-6 ;,'[f.J
19':
li1T ~ ( Case Study ) 248(~jt&~)
16-1
-ml:'tl
~ ( General Characteristics ) 25216-2 ~:11
'*
1t
~ (Clinical Significance ) 25316-3 ±gltf~;lftl:.:&iiJt7f5! ( Cultural Characteristics & Identification ) 254
16-4 ~
4m
fo!& ~·thi\.f)t
( Antimicrobial Susceptibility Testing ) 26116-5
Ai
Xf
/
ffi
f!jj ( Treatment/Prevenrion) 26116-6 ~ i9~ lfJt-~ ( Case Study) 262
( ~3t~~ )
171 -~~,t1 Jlr (General Characteristics ) 266 17-2 ~ ~:@:~ (Clinical Significance ) 266
17-3 115
fi-lt·1'i
.
&Jt
ltjj5! ( Cultural Characteristics & Identification ) 26717-4 ~
#J
~~ ~,t1-~~ (Antimicrobial Susceptibility Testing) 26817-5
nHn
( Prevention ) 26917-6 ~ i9~!iJf ~ ( Case study) 269
(~3t!w.
)
18-1
-M:'ti
j.r ( General Characteristics) 274II
\8-2 18-3 18-4 18-5 18-6 19-1 19-2 19-3 19-4 19-5 19-6 20-1 20-2 20-3 20-4 20-5 20-6 20-7 21-1 21-2 21-3 21-4 21-5 22-1 22-2 22-3 xiii~I7R
'.t-il
(Clinical Significance ) 274}ff
it
i~ ·~i.&.~Jt7J$. ( Cultural Characteristics & Identification) 274li4m
1.'$ ~·ti~~ ( Antimicrobial Susceptibility Testing ) 275fff
IW
( Prevention ) 275~ 17~
1i}f-:JE
(Case Study ) 275L
(~3t~)- ~Q:
·ri
~ ( General Characteristics ) 280~J~ ~;@: ~ ( Clinical Significance ) 280
*~"i;f·t.i&~.ltjj ~ (Cultural Characteristics & Identiiication ) 281
~#1
.tJ
~H
~~i ( Antimicrobial Susceptibility Testing ) 282ffi
IYJ (Prevention ) 283m
f91j"~f-Jt
(Case Study ) 283(
5Nlt!~,
~fa~Bi)
-M::·ti
~ ( General Characteristics ) 288Gra
fiR:t
~(
Clinical Significance ) 290J~w4~,ti&*.lt/J)! ( Cu ltural Characteri stics & Identification ) 297
m
fft
ill
~#; ( Antifungal Agents) 301jfJffi
/
ffi
IYJ/
:IJfE
ft
~*
( TreatmentlPrevention /Epidemiology ) 302~
E
ff.~'f.
tt
J..1j ( Techniques in Mycology Lab ) 303~
19
1]\iff
~ ( Case Study ) 3051 '''r
.. f'" -I _ _ ~ (~:&~)
-
MUiJf
( General Characteristics ) 308fri..i
"t
.:t.
i"l=ffJ
~ ~ ( Mechanisms of Antibiotic Resistance ) 308fri:
~·tt:::'
At...
( Mechanisms of Antibiotic Resistance ) 313~
4m
%
~,tt
~~ ( Antimicrobial Susceptibility Test ) 316~
iqu !iJf
~ (Case Study ) 328_.
___-
_
(
fiI~~)
1ltr~ 332
r7t
I*J
I,~!d~~.99
jJ\. ~.&. ~~ ~ 333_________________
__
_
________________
_
xi\'22-4
il'
Hi
~ ~tal,
~1l[)}l 33522-5
ir.d~
.
1J¥d:
.
#J~'
~
:tit
I1t
pt]~
~
~
:jQrjf!t
jQ±-
1:f
~f
~~
4J
a.
":'r-J -r~,*fy&
~4~*~~ifB
tJ
1lt
*
r----..---,
22-6 f#-jHtl'f.J~klJL ' q~.~1t~1t 33722-7 ~1~,jli}f~ ( Case Study ) 339
~
o+l j!f1 i~-
:
1:.tm~~~i"FtI
343tt
m.~:~~.~#J*$~M~a~~~~. 3M'fIl
'j m.~ : ~~~*~.&~~~a 3~
M
pfH~ [9 :lin.
:I{')~AITi:
71<.lit-ItiJN
36411 ~IHlll.
:
1mlrfi
7t!M
fi1j 11'- 367 *)C%,~1 373 ~ .:J:-'tf
)c%'
iJl
386 ~~ J.~ ~~ tI1 ~~ ~u ~q: ±/ c /j IJ../ ]fi, ~ m:~ 'i1 Umi,
E~i.,
t;J ~1; qJn ~ff ~ 33 7I
~~EI~I
*'~
.
I
I
I
I
I
___
L
_®f'H~~2js:M~
~ttf;ItJ
~'*M~~~~m~~~'*~U®~~W~~
~ruJ.m~~~~5lT~~fJ{f(q ~m_iil'l',JfIl~ 0 ~2js:frJ!i~~fJ{fijq o ~'*1l'fi~~tAA~m~%H~ 0 ~'*~ff1(j{]qt~~~;£ffi•
lfilm~J~¥~Ii@~?tT~I:J~:fJiffq 0
~'*~~~rr~~l¥Jd1~ o 'tf~*2(~ o ~'*~~~8'_JJTh~